V
53.01
2.24 (4.41%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Viking Therapeutics, Inc. | Bearish | - |
Stockmoo Score
1.3
|
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 120.00 (Truist Securities, 126.37%) | Buy |
| 120.00 (Maxim Group, 126.37%) | Buy | |
| Median | 116.00 (118.83%) | |
| Low | 90.00 (HC Wainwright & Co., 69.78%) | Buy |
| Average | 110.20 (107.89%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 56.04 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 27 Jun 2024 | 105.00 (98.08%) | Buy | 50.77 |
| HC Wainwright & Co. | 24 Jun 2024 | 90.00 (69.78%) | Buy | 52.12 |
| 04 Jun 2024 | 90.00 (69.78%) | Buy | 56.23 | |
| Truist Securities | 17 Jun 2024 | 120.00 (126.37%) | Buy | 52.02 |
| 16 May 2024 | 120.00 (126.37%) | Buy | 69.06 | |
| Maxim Group | 04 Jun 2024 | 120.00 (126.37%) | Buy | 56.23 |
| Raymond James | 16 May 2024 | 116.00 (118.83%) | Buy | 69.06 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |